Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old m...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.929763/full |
| _version_ | 1811199190739451904 |
|---|---|
| author | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin |
| author_facet | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin |
| author_sort | Sha-Sha Wang |
| collection | DOAJ |
| description | The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma. |
| first_indexed | 2024-04-12T01:43:51Z |
| format | Article |
| id | doaj.art-4a3b48ec7e094029bef3ca8a4f81c6e3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T01:43:51Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4a3b48ec7e094029bef3ca8a4f81c6e32022-12-22T03:53:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.929763929763Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patientSha-Sha Wang0Fang Wang1Zhen Zeng2Fang Gao3Huan-Huan Liu4Hui-Na Wang5Yi Hu6Hai-Feng Qin7Department of Oncology, Chinese People's Liberation Army General Hospital, Beijing, ChinaDepartment of Internal Medicine, OASIS International Hospital, Beijing, ChinaDepartment of Oncology, Chinese People's Liberation Army General Hospital, Beijing, ChinaDepartment of Oncology, Chinese People's Liberation Army General Hospital, Beijing, ChinaDepartment of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, ChinaDepartment of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, ChinaDepartment of Oncology, Chinese People's Liberation Army General Hospital, Beijing, ChinaDepartment of Oncology, Chinese People's Liberation Army General Hospital, Beijing, ChinaThe identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma.https://www.frontiersin.org/articles/10.3389/fonc.2022.929763/fullRET intergenic fusionpralsetiniblung adenocarcinomanovel intergenictyrosine kinase inhibitors |
| spellingShingle | Sha-Sha Wang Fang Wang Zhen Zeng Fang Gao Huan-Huan Liu Hui-Na Wang Yi Hu Hai-Feng Qin Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Frontiers in Oncology RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors |
| title | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_fullStr | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full_unstemmed | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_short | Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_sort | case report a novel intergenic mir4299 mir8070 ret fusion with ret amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| topic | RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.929763/full |
| work_keys_str_mv | AT shashawang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT fangwang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT zhenzeng casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT fanggao casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huanhuanliu casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huinawang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT yihu casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT haifengqin casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient |